Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning.


Journal

Psycho-oncology
ISSN: 1099-1611
Titre abrégé: Psychooncology
Pays: England
ID NLM: 9214524

Informations de publication

Date de publication:
05 2019
Historique:
received: 08 10 2018
revised: 22 02 2019
accepted: 25 02 2019
pubmed: 1 3 2019
medline: 28 3 2020
entrez: 1 3 2019
Statut: ppublish

Résumé

To identify and characterize distinct trajectories of change in young women's sexual functioning over the first 5 years following breast cancer diagnosis. Group-based trajectory modeling was applied to the sexual functioning of 896 women diagnosed with stage I-IV breast cancer at age 40 or younger. The Cancer Rehabilitation Evaluation System was used to evaluate women's symptoms of sexual dysfunction annually for 5 years. Five distinct trajectories of sexual functioning were identified: one asymptomatic, one minimally symptomatic, two moderately symptomatic, and one severely symptomatic trajectory. Twelve percent of women were asymptomatic throughout follow-up. The plurality of women experienced stable mild symptoms (42%). Among those with moderate symptoms, some experienced improvement over time (22%) while others experienced deterioration (13%); 11% experienced stable severe symptoms that did not remit over time. Independent predictors of experiencing a symptomatic rather than asymptomatic trajectory (P < 0.05, two-sided) included diagnosis with stage 2 versus 1 disease, ER positive disease treated with oophorectomy or ovarian suppression, being partnered, having anxiety, poorer body image, and greater musculoskeletal pain. We identified distinct trajectories that describe the reported sexual symptoms in this cohort of young breast cancer survivors. The majority of women reported various degrees of sexual dysfunction that remained stable over the study period. There is, however, potential for improvement of moderate and severe symptoms of sexual dysfunction in early survivorship.

Identifiants

pubmed: 30817075
doi: 10.1002/pon.5047
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0
Receptors, Estrogen 0
Tamoxifen 094ZI81Y45
Leuprolide EFY6W0M8TG

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1033-1040

Subventions

Organisme : NCI NIH HHS
ID : NIH 3R25CA057711
Pays : United States
Organisme : Susan G. Komen
Pays : United States

Informations de copyright

© 2019 John Wiley & Sons, Ltd.

Auteurs

Christiana von Hippel (C)

Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Shoshana M Rosenberg (SM)

Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

S Bryn Austin (SB)

Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Kim Sprunck-Harrild (K)

Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Kathryn J Ruddy (KJ)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Lidia Schapira (L)

Division of Medical Oncology, Stanford University Medical Center, Stanford, California.

Steven Come (S)

Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Virginia F Borges (VF)

Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado.

Ann H Partridge (AH)

Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH